MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Happened with aTyr Pharma's Initial Phase 3 Trial

2 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Do the SYNAPSE-CMT Phase 2a Results Mean for NMD Pharma

1 months ago

What Happened with Olaplex's Q4 2025 Earnings

4 months ago

What Happened with Cerebras Systems' Blockbuster IPO

2 months ago

What Just Happened with Praxis's Vormatrigine Program

1 months ago

Ionis, AstraZeneca Pivotal Heart Disease Drug Flunks

Ionis and AstraZeneca's Phase 3 study of eplontersen for ATTR-CM failed to meet its primary efficacy endpoint, a major setback for the heart disease drug.

AZN

Stock News•1 months ago

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

Novartis del-brax Phase I/II FORTITUDE study met primary and key secondary endpoints, reducing KHDC1L and creatine kinase levels in FSHD patients. Safety profile was consistent with prior results. Pha...

NVS

Stock News•1 months ago

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape

Amylyx Pharmaceuticals faces a Q3 Phase 3 readout for avexitide in post-bariatric hypoglycemia, with launch plans taking shape. The outcome could determine the company's near-term trajectory.

PBH

Stock News•2 months ago

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma will initiate a new Phase III trial for efzofitimod in pulmonary sarcoidosis following recent feedback from the FDA. This strategic pivot follows a Type C meeting with regulators to align ...

ATYR